(0.22%) 5 142.75 points
(0.21%) 38 521 points
(0.31%) 17 900 points
(-0.99%) $83.02
(1.56%) $1.953
(-0.32%) $2 339.70
(-0.27%) $27.46
(0.29%) $924.80
(-0.17%) $0.933
(-0.13%) $11.01
(-0.24%) $0.798
(0.78%) $92.59
Live Chart Being Loaded With Signals
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments...
Stats | |
---|---|
本日の出来高 | 154.00 |
平均出来高 | 91.00 |
時価総額 | 1.87B |
EPS | $27.56 ( 2023-09-30 ) |
Last Dividend | $0.105 ( 2022-09-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | 11.94 |
ATR14 | $0 (0.00%) |
Nippon Shinyaku Co., Ltd. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Nippon Shinyaku Co., Ltd. 財務諸表
Annual | 2023 |
収益: | $144.18B |
総利益: | $88.20B (61.17 %) |
EPS: | $338.70 |
FY | 2023 |
収益: | $144.18B |
総利益: | $88.20B (61.17 %) |
EPS: | $338.70 |
FY | 2022 |
収益: | $137.48B |
総利益: | $87.29B (63.49 %) |
EPS: | $370.97 |
FY | 2021 |
収益: | $121.89B |
総利益: | $71.93B (59.02 %) |
EPS: | $76.84 |
Financial Reports:
No articles found.
Nippon Shinyaku Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.105 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0575 | 2017-10-02 |
Last Dividend | $0.105 | 2022-09-29 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $1.029 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.11 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.36 | |
Div. Directional Score | 10.00 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TRBK | Ex Dividend Junior | 2023-08-03 | Semi-Annually | 0 | 0.00% | |
ITJTY | Ex Dividend Junior | 2023-10-31 | Annually | 0 | 0.00% | |
BKKPF | Ex Dividend Junior | 2023-09-06 | Annually | 0 | 0.00% | |
PUODY | Ex Dividend Knight | 2023-06-21 | Annually | 0 | 0.00% | |
EPOKY | Ex Dividend Knight | 2023-10-23 | Semi-Annually | 0 | 0.00% | |
VDMCY | Ex Dividend Knight | 2023-06-22 | Semi-Annually | 0 | 0.00% | |
KSBI | Ex Dividend Knight | 2023-07-28 | Quarterly | 0 | 0.00% | |
CGEMY | Ex Dividend Knight | 2023-05-25 | Annually | 0 | 0.00% | |
SCGLY | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
FSUGY | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.164 | 1.500 | 6.72 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0974 | 1.200 | 6.75 | 8.10 | [0 - 0.3] |
returnOnEquityTTM | 0.117 | 1.500 | 9.81 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.331 | -1.000 | 6.69 | -6.69 | [0 - 1] |
currentRatioTTM | 5.92 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.17 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.11 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00826 | -1.500 | 9.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 264.20 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 321.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 163.50 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00953 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.646 | 1.000 | 2.57 | 2.57 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.226 | 1.000 | 7.47 | 7.47 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 10.59 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.593 | 0.800 | 9.38 | 7.50 | [0.5 - 2] |
Total Score | 13.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.06 | 1.000 | 9.79 | 0 | [1 - 100] |
returnOnEquityTTM | 0.117 | 2.50 | 9.88 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 163.50 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.00961 | 1.500 | 9.76 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 321.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.331 | 1.500 | 6.69 | -6.69 | [0 - 1] |
pegRatioTTM | 0.000693 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.147 | 1.000 | 8.81 | 0 | [0.1 - 0.5] |
Total Score | 6.36 |
Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。